Tanvex BioPharma Inc Cash Flow-to-Debt Ratio
Tanvex BioPharma Inc cash flow-to-debt ratio. Tanvex BioPharma Inc (6541) has a Cash Flow-to-Debt Ratio of -0.14x as of March 2026, meaning its operating cash flow of NT$-309.37 Million could theoretically repay 0% of its total liabilities (NT$2.27 Billion) in one year. See Tanvex BioPharma Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Tanvex BioPharma Inc (2013–2025)
Cash flow-to-debt ratio of Tanvex BioPharma Inc from 2013 to 2025. Historical debt coverage capacity for Tanvex BioPharma Inc across 13 annual periods. Also explore Tanvex BioPharma Inc (6541) net asset momentum to track the company's year-over-year net asset growth rate.
Tanvex BioPharma Inc Cash Flow-to-Debt Ratio by Year (2013–2025)
Tanvex BioPharma Inc cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Tanvex BioPharma Inc. For the full cash flow conversion analysis, see Tanvex BioPharma Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.44x | NT$-1.01 Billion | NT$2.27 Billion | ▲ +29.0% |
| 2024 | -0.62x | NT$-1.15 Billion | NT$1.84 Billion | ▲ +15.4% |
| 2023 | -0.74x | NT$-1.43 Billion | NT$1.94 Billion | ▼ -12.3% |
| 2022 | -0.66x | NT$-1.33 Billion | NT$2.03 Billion | ▲ +9.0% |
| 2021 | -0.72x | NT$-1.39 Billion | NT$1.92 Billion | ▲ +29.2% |
| 2020 | -1.02x | NT$-1.79 Billion | NT$1.75 Billion | ▲ +70.9% |
| 2019 | -3.50x | NT$-1.90 Billion | NT$542.12 Million | ▲ +42.4% |
| 2018 | -6.08x | NT$-1.61 Billion | NT$263.92 Million | ▼ -12.3% |
| 2017 | -5.42x | NT$-1.21 Billion | NT$223.78 Million | ▼ -94.5% |
| 2016 | -2.79x | NT$-833.43 Million | NT$299.25 Million | ▲ +50.6% |
| 2015 | -5.64x | NT$-684.20 Million | NT$121.41 Million | ▲ +15.5% |
| 2014 | -6.67x | NT$-434.17 Million | NT$65.09 Million | ▼ -132.5% |
| 2013 | -2.87x | NT$-239.86 Million | NT$83.63 Million | — |